In vitro and in vivo antimicrobial activity of two alpha-helical cathelicidin peptides and of their synthetic analogs
- PMID: 15019203
- PMCID: PMC7124310
- DOI: 10.1016/j.peptides.2003.07.025
In vitro and in vivo antimicrobial activity of two alpha-helical cathelicidin peptides and of their synthetic analogs
Abstract
Two alpha-helical antimicrobial peptides (BMAP-27 and -28) and four synthetic analogs were compared for in vitro and in vivo antimicrobial efficacy. All peptides proved active in vitro at micromolar concentrations against a range of clinical isolates, including antibiotic-resistant strains. BMAP-27 and two analogs were more effective towards Gram-negative, and BMAP-28 towards Gram-positive organisms. In addition, BMAP-28 provided some protection in vitro against human herpes simplex virus type 1 (HSV-1). The parent peptides and mBMAP-28 analog protected mice from lethal i.p. infections in an acute peritonitis model at peptide doses significantly lower than those toxic to the animals, suggesting a satisfactory therapeutic index.
Figures
References
-
- Ahmad I., Perkins W.R., Lupan D.M., Selsted M.E., Janoff A.S. Liposomal entrapment of the neutrophil-derived peptide indolicidin endows it with in vivo antifungal activity. Biochim. Biophys. Acta. 1995;1237:109–114. - PubMed
-
- Borenfreund E., Puerner J.A. Toxicity determined in vitro by morphological alterations and neutral red adsorption. Toxicol Lett. 1985;24:119–124. - PubMed
-
- Buck M.A., Olah T.A., Weitzmann C.J., Cooperman B.S. Protein estimation by the product of integrated peak area and flow rate. Anal. Biochem. 1989;182:295–299. - PubMed
-
- Chen J., Falla T.J., Liu H., Hurst M.A., Fujii C.A., Mosca D.A. Development of protegrins for the treatment and prevention of oral mucositis: structure–activity relationships of synthetic protegrin analogues. Biopolymers. 2000;55:88–98. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
